Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

A novel bispecific antibody platform to direct complement activity for efficient lysis of target cells.

Cruz JW, Damko E, Modi B, Tu N, Meagher K, Voronina V, Gartner H, Ehrlich G, Rafique A, Babb R, Aneja P, Potocky TB, D' Orvilliers A, Coppi A, E SY, Qiu H, Williams CM, Bennett BL, Chen G, Macdonald L, Olson W, Lin JC, Stahl N, Murphy AJ, Kyratsous CA, Prasad BC.

Sci Rep. 2019 Aug 19;9(1):12031. doi: 10.1038/s41598-019-48461-1.

2.

Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice.

Burova E, Hermann A, Dai J, Ullman E, Halasz G, Potocky T, Hong S, Liu M, Allbritton O, Woodruff A, Pei J, Rafique A, Poueymirou W, Martin J, MacDonald D, Olson WC, Murphy A, Ioffe E, Thurston G, Mohrs M.

Mol Cancer Ther. 2019 Nov;18(11):2051-2062. doi: 10.1158/1535-7163.MCT-18-1376. Epub 2019 Aug 8.

PMID:
31395688
3.

A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.

Crawford A, Haber L, Kelly MP, Vazzana K, Canova L, Ram P, Pawashe A, Finney J, Jalal S, Chiu D, Colleton CA, Garnova E, Makonnen S, Hickey C, Krueger P, DelFino F, Potocky T, Kuhnert J, Godin S, Retter MW, Duramad P, MacDonald D, Olson WC, Fairhurst J, Huang T, Martin J, Lin JC, Smith E, Thurston G, Kirshner JR.

Sci Transl Med. 2019 Jun 19;11(497). pii: eaau7534. doi: 10.1126/scitranslmed.aau7534.

PMID:
31217340
4.

Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates.

Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL, Fairhurst J, Torres M, Rafique A, Yan Y, Badithe A, Yu K, Potocky T, Bixler SL, Chance TB, Pratt WD, Rossi FD, Shamblin JD, Wollen SE, Zelko JM, Carrion R Jr, Worwa G, Staples HM, Burakov D, Babb R, Chen G, Martin J, Huang TT, Erlandson K, Willis MS, Armstrong K, Dreier TM, Ward AB, Davey RA, Pitt MLM, Lipsich L, Mason P, Olson W, Stahl N, Kyratsous CA.

J Infect Dis. 2018 Nov 22;218(suppl_5):S612-S626. doi: 10.1093/infdis/jiy285.

5.

Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody-Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers.

Kelly MP, Hickey C, Makonnen S, Coetzee S, Jalal S, Wang Y, Delfino F, Shan J, Potocky TB, Chatterjee I, Andreev J, Kunz A, D'Souza C, Giurleo JT, Nittoli T, Trail PA, Thurston G, Kirshner JR.

Mol Cancer Ther. 2017 Jul;16(7):1299-1311. doi: 10.1158/1535-7163.MCT-16-0839. Epub 2017 Apr 4.

6.

Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.

Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q, D'Orvilliers A, Garnova E, Rafique A, Poueymirou W, Martin J, Huang T, Skokos D, Kantrowitz J, Popke J, Mohrs M, MacDonald D, Ioffe E, Olson W, Lowy I, Murphy A, Thurston G.

Mol Cancer Ther. 2017 May;16(5):861-870. doi: 10.1158/1535-7163.MCT-16-0665. Epub 2017 Mar 6.

7.

Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.

MacDonald DA, Martin J, Muthusamy KK, Luo JK, Pyles E, Rafique A, Huang T, Potocky T, Liu Y, Cao J, Bono F, Delesque N, Savi P, Francis J, Amirkhosravi A, Meyer T, Romano C, Glinka M, Yancopoulos GD, Stahl N, Wiegand SJ, Papadopoulos N.

Angiogenesis. 2016 Jul;19(3):389-406. doi: 10.1007/s10456-016-9515-8. Epub 2016 May 27.

8.

Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice.

Latres E, Pangilinan J, Miloscio L, Bauerlein R, Na E, Potocky TB, Huang Y, Eckersdorff M, Rafique A, Mastaitis J, Lin C, Murphy AJ, Yancopoulos GD, Gromada J, Stitt T.

Skelet Muscle. 2015 Oct 9;5:34. doi: 10.1186/s13395-015-0060-8. eCollection 2015.

9.

ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models.

Zhang L, Castanaro C, Luan B, Yang K, Fan L, Fairhurst JL, Rafique A, Potocky TB, Shan J, Delfino FJ, Shi E, Huang T, Martin JH, Chen G, Macdonald D, Rudge JS, Thurston G, Daly C.

Mol Cancer Ther. 2014 May;13(5):1345-55. doi: 10.1158/1535-7163.MCT-13-1033. Epub 2014 Mar 14.

10.

Inhibition of herpes simplex virus type 1 infection by cationic beta-peptides.

Akkarawongsa R, Potocky TB, English EP, Gellman SH, Brandt CR.

Antimicrob Agents Chemother. 2008 Jun;52(6):2120-9. doi: 10.1128/AAC.01424-07. Epub 2008 Apr 7.

11.

Deconvolution of the cellular oxidative stress response with organelle-specific Peptide conjugates.

Mahon KP, Potocky TB, Blair D, Roy MD, Stewart KM, Chiles TC, Kelley SO.

Chem Biol. 2007 Aug;14(8):923-30.

12.

HeLa cell entry by guanidinium-rich beta-peptides: importance of specific cation-cell surface interactions.

Potocky TB, Silvius J, Menon AK, Gellman SH.

Chembiochem. 2007 May 25;8(8):917-26.

PMID:
17503427
13.

Crystallization of bacteriorhodopsin solubilized by a tripod amphiphile.

Theisen MJ, Potocky TB, McQuade DT, Gellman SH, Chiu ML.

Biochim Biophys Acta. 2005 Aug 10;1751(2):213-6.

PMID:
15963773
14.

Effects of conformational stability and geometry of guanidinium display on cell entry by beta-peptides.

Potocky TB, Menon AK, Gellman SH.

J Am Chem Soc. 2005 Mar 23;127(11):3686-7.

PMID:
15771489
15.

Cytoplasmic and nuclear delivery of a TAT-derived peptide and a beta-peptide after endocytic uptake into HeLa cells.

Potocky TB, Menon AK, Gellman SH.

J Biol Chem. 2003 Dec 12;278(50):50188-94. Epub 2003 Sep 29.

Supplemental Content

Loading ...
Support Center